Background: Older adults with acute myeloid leukemia (AML) represent a vulnerable
population in whom disease-based and clinical risk factors, patient goals, prognosis, and …

In 2003, an international working group last reported on recommendations for diagnosis,
response assessment, and treatment outcomes in acute myeloid leukemia (AML). Since that …

Background Recent studies have provided a detailed census of genes that are mutated in
acute myeloid leukemia (AML). Our next challenge is to understand how this genetic …

Underpinning the vision of precision medicine is the concept that causative mutations in a
patient's cancer drive its biology and, by extension, its clinical features and treatment …

Retinoic acid (RA), the major bioactive metabolite of retinol or vitamin A, induces a spectrum
of pleiotropic effects in cell growth and differentiation that are relevant for embryonic …

To assess the frequency of TP53 alterations and their correlation with other genetic changes
and outcome in acute myeloid leukemia with complex karyotype (CK-AML), we performed …

The concept of differentiation therapy emerged from the fact that hormones or cytokines may
promote differentiation ex vivo, thereby irreversibly changing the phenotype of cancer cells …

To study the characteristics and clinical impact of therapy-related acute myeloid leukemia (t-
AML). 200 patients (7.0%) had t-AML and 2653 de novo AML (93%). Patients with t-AML …

We evaluated the frequency, genetic architecture, clinico-pathologic features and prognostic
impact of RUNX1 mutations in 2439 adult patients with newly-diagnosed acute myeloid …

All-trans retinoic acid (ATRA), an active metabolite of vitamin A, plays important roles in cell
proliferation, cell differentiation, apoptosis, and embryonic development. The effects of ATRA …